July 2010 Newsletter Now Available

Top stories from TTO's July 2010 newsletter:

Western States Biopharma to Commercialize CU Autoimmune Disease Treatment
Western States Biopharmaceuticals, Inc. (WSBI), a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM™ autoimmune disease drug discovery targets. WSBI is currently advancing its lead molecule – WSBI-711, an antibody against two TCISM targets – into midstage pre-clinical testing. WSBI’s other promising TCISM antibody and orally-active small molecule therapeutic programs are also progressing towards pre-clinical development.


Syberenety Options Addiction Support Software from CU
A social networking tool developed jointly by the University of Colorado at Colorado Springs and Syberenety LLC may soon be available to help recovering addicts stay connected to support and accountability. Through an interactive, online social support network environment, coupled with applications on a handheld device, users will stay connected in real-time with professional and personal mentors, to give those battling addiction the best chance at avoiding and coping with potential relapse. Technology underlying the social network tool was recently optioned to Syberenety LLC, a Colorado-based company seeking to help those recovering from addiction find support in a secure online network.


Sandhill Scientific Options CU Diagnostic Device for Esophageal Diseases
A diagnostic device developed at the University of Colorado Denver School of Medicine and the University of Illinois at Chicago College of Medicine was recently optioned by Sandhill Scientific, Inc., a Colorado-based company developing diagnostic devices for a variety of gastrointestinal illnesses. Diagnosing inflammatory conditions of the gastrointestinal tract such as severe gastroesophageal reflux (GERD), eosinophilic esophagitis (EoE), inflammatory bowel disease (lBD), and a number of other diseases can be difficult. Blood, stool and x-ray tests are not sufficient to diagnose any of these conditions definitively, or to differentiate them, and more invasive methods such as endoscopy are costly and carry potential complications. The optioned technology provides a less invasive way for doctors to determine the cause and appropriate treatment of esophageal inflammation.

miRagen teams with Santaris Pharma

RealD Dazzles in IPO Debut

Read the full newsletter, or sign up to receive a monthly email update.